At a glance
ClinicalIndex Comparison RecordN/ACompleted· 4 enrolled
Drug / intervention
vancomycin +1 moredrug
Likely dose
vancomycin 30 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections
In Brief
A clinical study evaluating vancomycin for Skin and Soft Tissue Infections. Completed, enrolled 4 participants across 1 site.
Detailed Summary
Our hypothesis is that large-dose, extended-interval vancomycin (30 mg/kg IV q24h) administration provides non-inferior clinical efficacy and microbiological efficacy to standard vancomycin (15 mg/kg IV q12h) administration for skin and soft tissue infections in an outpatient setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin and Soft Tissue Infections
CountriesCanada
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartMar 2010
Primary CompletionSep 2010
TodayJul 2026
First PostedDec 22, 2009
Enrollment StartMar 1, 2010
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.5 years ago
Interventions
vancomycindrug
vancomycin 30 mg/kg intravenous administered once daily
vancomycindrug
vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)